Diabetes Mellitus and Noncardiac Atherosclerotic Vascular Disease-Pathogenesis and Pharmacological Treatment Options

被引:14
|
作者
Muzurovic, Emir M. [1 ,2 ]
Mikhailidis, Dimitri P. [3 ]
机构
[1] Clin Ctr Montenegro, Endocrinol Sect, Dept Internal Med, Podgorica, Montenegro
[2] Univ Montenegro, Fac Med, Podgorica, Montenegro
[3] Univ Coll London UCL, Med Sch, Dept Clin Biochem, Royal Free Hosp Campus, London, England
关键词
diabetes mellitus; noncardiac atherosclerotic vascular disease; pharmacological treatment; cardiovascular outcome trials; stroke; peripheral artery disease; renal artery stenosis; aortic aneurysm; RENAL-ARTERY STENOSIS; ABDOMINAL AORTIC-ANEURYSMS; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; DENSITY-LIPOPROTEIN-CHOLESTEROL; PIOGLITAZONE CLINICAL-TRIAL; ASSOCIATION TASK-FORCE; CARDIOVASCULAR-DISEASE; RISK-FACTORS; INTRACEREBRAL HEMORRHAGE; CAROTID ATHEROSCLEROSIS;
D O I
10.1177/1074248420941675
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus (DM) is also a cause of cardiovascular (CV) disease (CVD). Addressing the atherosclerotic CVD (ASCVD) burden in DM should reduce premature death and improve quality of life. Diabetes mellitus-associated ASCVD can lead to complications in all vascular beds (carotids as well as coronary, lower extremity, and renal arteries). This narrative review considers the diagnosis and pharmacological treatment of noncardiac atherosclerotic vascular disease (mainly in patients with DM). Based on current knowledge and the fact that modern DM treatment guidelines are based on CV outcome trials, it should be noted that patients with noncardiac CVD may not have the same benefits from certain drugs compared with patients who predominantly have cardiac complications. This leads to the conclusion that in the future, consideration should be given to conducting well-designed trials that will answer which pharmacological treatment modalities will be of greatest benefit to patients with noncardiac ASCVD.
引用
收藏
页码:25 / 39
页数:15
相关论文
共 50 条